Author: Kathir J

  • The Launch Press Conference of the 6th Lushan International Romance Film Week Held, Activating a New Business Model of “Movie and Tourism Integration”

    Beijing, China – On August 21, the Launch Press Conference of the 6th Lushan International Romance Film Week, themed “Green Wild Love Letter, Cinematic Lushan”, was held in Beijing. As a cultural brand carefully crafted by Lushan City, the Lushan International Love Film Week leverages the world cultural heritage of Lushan and its position as a landmark of Chinese Love Film culture, making it an important window to showcase the natural and cultural charm of Lushan. This year’s Film Week, themed “Fall in Love with Films”, will feature classic love films, immersive cultural and tourism experiences, and various other activities to promote deep integration between films and tourism, empowering tourism consumption and industrial revitalization through movie IP.

    Mountains and waters convey emotions, representing the ultimate romance unique to the Chinese people. Since its inception in 2020, the Lushan International Love Film Week has been held for five consecutive years, successfully integrating Lushan’s natural beauty and cultural heritage into cinematic art. It has explored the “Lushan Path” of transforming cultural resources into economic momentum and elevating local brands into international symbols. This year, marking the 120th anniversary of Chinese cinema, the 6th Lushan International Romance Film Week continues the theme of the 5th edition, “Lushan, Your Pillar of Love”, and innovatively launches the “Fall in Love with Films” sweet project, offering Chinese cinema a timeless romantic tribute.

    At the launch press conference, the Film Week Ambassador Chen Jianbin and Jiang Qinqin interacted remotely, sending beautiful blessings to all those who believe in love, yearn for love, and are currently in love, drawing inspiration from Lushan’s majestic grandeur and its towering waterfalls. “Fall in Love with Films” ambassador Li Xiaomeng voiced over a classic scene from the film “Romance on Lushan Mountain”, recreating the emotionally stirring love story. The group Shuimunianhua performed the theme song “I’m Waiting for You in Lushan”, marking the sparkling opening of this love-themed cinematic journey.

    During the Film Week, Lushan will present three major highlight activities centered around the theme “Fall in Love with Films”, including an all-encompassing immersive film-tourism experience, high-level exchanges between filmmakers and the tourism industry, as well as a magnificent celebration and heartfelt interactions. The “New Century Top Ten Love Films Recommendation” event, supported by the Chinese Film Critics Society, along with the “2024 Annual Love Film Main Creative Honors”, will also be officially announced during the event.

    As another successful example of CMG’s deepened central-local collaboration and co-creation model, this year’s Lushan International Love Film Festival will fully leverage the communication strengths of national media and the resource advantages of local industries. It aims to further integrate film culture with regional characteristics, solidify the festival’s brand identity as the “Lushan, Your Pillar of Love” – a phrase increasingly rooted in public awareness – and strengthen its systematic and long-term catalytic effect on related industries. The event continues to develop into a top-tier romantic film celebration in China with growing international influence.

    This year’s event will be fully showcased on  China Media Group’s Mobile, the new media platform of CMG. Compared to previous years, China Media Group’s Mobile will provide richer content formats and communication channels for the Lushan International Love Film Festival. Leveraging the resources of a national-level new media platform, it will innovatively launch special activities such as opening-day live streams and experience vlogs during the festival, while also initiating online topics and trending discussions on social media. These efforts will not only enable the scenic romance of Lushan to reach a wider audience through the cloud but also foster emotional resonance across the internet around the theme “Fall in Love with Films”.

    From September 5 to 11, let’s meet at the 6th Lushan International Romance Film Week, to experience the screen romance amidst the mist, to savor the enchanting scenery both on and off camera, and to witness Lushan, a landmark of love culture, in its innovative practices and vibrant charm.

  • COOFANDY Men’s Shirt Receives CNN Underscored Recommendation, Officially Launches 2025 Autumn/Winter New Collection

    COOFANDY, a leader in men’s fashion, proudly announces that its Men’s Casual Button-Down Shirt has been selected as a 2025 Editor’s Pick by CNN Underscored, CNN’s product recommendation source.

    About the CNN Recognition

    The COOFANDY Men’s Casual Button-Down Shirt was highlighted by CNN in their “Editor’s Favorite Products” for June 2025. This recognition underscores the men’s shirt‘s exceptional quality, style, and value, affirming its status as a modern menswear essential.

    The review from CNN Underscored regarding this men’s casual button-down shirt states: “I love it when someone compliments me on a shirt I’m wearing and I get to respond: ‘Thanks! I got it on Amazon for, like, 20 bucks.’ That’s the case with this COOFANDY button-down, which is exceptionally comfortable and lightweight, yet still polished enough to wear to the office or out for a night on the town. I’ve had a few of these men‘s shirts for years, but they became even more indispensable during this record-breaking NYC heat wave.”– Mike Andronico

    You can read the full feature highlighted by CNN

    COOFANDY Autumn/Winter Collection Now Available, Including Stylist Collaboration

    Building on the CNN Underscored recommendation, COOFANDY has launched its new Autumn/Winter collection, now available for purchase on Amazon. The collection features a variety of styles designed to elevate seasonal wardrobes, including an exclusive collection curated in collaboration with renowned stylist Britt Theodora.

    Outfit Recommendations:

    Men’s Plaid Button-Down Flannel Shirt: Crafted from soft and thick cotton flannel fabric, this shirt offers a warm and comfortable touch with excellent warmth retention, making it an essential piece for building layered looks.

    Men’s Mock Neck Long Sleeve Shirt: Its unique diamond pattern enhances the overall texture and sophistication, adding rich visual layers to the outfit whether worn open or buttoned.

    Men’s Casual Elastic Drawstring Trousers: Paired with these simple twill casual pants, the upper body’s patterns and textures are perfectly balanced, creating a well-proportioned look that is both refined and fashionable.

    This season’s Autumn/Winter outfit from COOFANDY masterfully blends classic checks, utilitarian practicality, and modern tailoring to create an urban sophisticate look that combines style with warmth. The core of this ensemble lies in its exceptional **layering** capabilities and **versatility**; each piece can harmoniously coordinate with others or stand alone, easily adapting to the changeable autumn and winter climate and various social occasions.

    COOFANDY Flannel Featured Series

    The artisanal flannel men‘s shirts from the COOFANDY Flannel Series are more than just COOFANDY products; they are a cornerstone of the brand’s identity and a testament to its commitment to comfort, quality, and timeless style. The iconic flannel shirt collection is meticulously crafted from premium brushed cotton fabric, offering an incredibly soft touch and exceptional insulation against the cold. Each shirt features both classic and contemporary patterns, from traditional buffalo checks and tartans to modern, subtle tonal plaids, ensuring a design for every preference.

    Beyond their signature look, these men‘s shirts are designed for versatility and durability. Attention to detail is evident in the reinforced stitching, sturdy buttons, and thoughtful fit, allowing for easy layering. Whether worn as a standalone statement piece on a crisp autumn day or as a cozy mid-layer under a jacket for winter adventures, COOFANDY’s flannels deliver unparalleled comfort and rugged reliability, season after season.

    About COOFANDY

    COOFANDY is an international brand dedicated to meeting the dressing needs of modern men. Adhering to the “Dress the Journey” philosophy, it is committed to providing men with high-quality, stylish, and cost-effective clothing options at every stage of life, accompanying them on their growth journey and exploring diverse styles.

    For more information, please visit the COOFANDY website and Amazon storefront, or connect with COOFANDY on Facebook and Instagram.

    COOFANDY

    Charlotte Liu

    pr@coofandy.com

    New York, US

    https://coofandy.com

  • CGTN: 60 years on, how China’s Xizang achieves all-round progress in development, prosperity

    On the 60th anniversary of the founding of China’s Xizang Autonomous Region, CGTN published an article highlighting the region’s remarkable social and economic progress over the past six decades. The article emphasizes that Xizang, under President Xi Jinping’s leadership, has experienced unprecedented development and significant changes, with people enjoying increasingly tangible benefits.

    A grand gathering to celebrate the 60th anniversary of the founding of China’s Xizang Autonomous Region was held at the Potala Palace square in Lhasa on Thursday morning. Chinese President Xi Jinping joined around 20,000 local officials and people from all ethnic groups and all walks of life in the celebration.

    Dressed in festive attire, crowds waved red flags and flower bouquets, extending a warm welcome to President Xi, who was also presented with a hada – a scarf-like white silk used by people in Xizang to show respect and blessings.

    In a historic first for both the Party and the country, Xi led a central delegation to attend events marking the anniversary of the founding of the Xizang Autonomous Region as general secretary of the Communist Party of China (CPC) Central Committee, Chinese president and chairman of the Central Military Commission.

    Hearing work reports from the CPC Xizang regional committee and the regional government on Wednesday, Xi urged efforts to build a modern socialist new Xizang that is united, prosperous, civilized, harmonious and beautiful, calling on the region to advance high-quality development and continue to make solid efforts on the four main tasks of ensuring stability, facilitating development, protecting the eco-environment and strengthening the borders.

    Profound changes

    Kala Village of Xizang’s Nyingchi City was once an impoverished and isolated village, where logging, herding and growing highland barley were the main means of livelihood for the villagers.

    The turning point came in 2015 when a paired assistance team from Guangdong Province, tasked with aiding Xizang, took full advantage of the village’s cultural and tourism resources, identifying tourism featuring peach blossom as the breakthrough point to accelerate the village’s development.

    In 1998, villagers earned 2,000 yuan (around $276) from tourism, while in 2024, Kala Village welcomed over 110,000 visitors savoring the peach blossoms, with tourism revenue topping 3.7 million yuan. From relying solely on its natural resources to developing a thriving “peach blossom economy,” Kala Village’s vibrant practice of rural revitalization has made it a microcosm of Xizang’s broader progress.

    Since 2012, Xi has elevated Xizang’s strategic position to a new level, and presided over two central symposiums on work in Xizang, defining guiding principles, objectives and tasks in the new era. To date, Xizang has experienced a period of unprecedented development and momentous change, with people enjoying more and more tangible benefits. It showcases the remarkable success of China’s system of regional ethnic autonomy.

    Figures highlight Xizang’s historic progress in economic and social development. The region’s GDP hit 276.5 billion yuan in 2024, 154 times that of 1965, reaching an average annual growth rate of 8.9 percent. The per capita disposable income of urban and rural residents increased from 456 yuan and 108 yuan respectively in 1965 to 55,444 yuan and 21,578 yuan in 2024.

    Notably, the region has eliminated millennia-old absolute poverty and realized a moderately prosperous society in all respects alongside the rest of the nation. The transformation of people’s daily lives is evident – moving from buckets of water, oil lamps and dirt paths to running tap water, electric lights and paved roads. Xizang residents now have access to services such as the internet, rail and air travel.

    Governing Xizang, ensuring its stability and promoting its prosperity must begin with maintaining political and social stability, ethnic unity and amity among different religions, Xi pointed out during Wednesday’s meeting.

    Building a modern socialist new Xizang

    In addition to the peach blossom economy, Kala Village has also diversified its income sources through ways such as the introduction of fruit-picking gardens and organized planting and breeding projects, forging a path to prosperity that achieves a win-win result between ecological conservation and economic development.

    How to promote Xizang’s high-quality development? Xi pinpointed during Wednesday’s meeting: “Xizang needs to develop competitive plateau industries based on local conditions, with a particular focus on industries of agriculture and animal husbandry with local features, as well as the clean energy sector.”

    In recent years, the region has continued to enhance its distinctive and advantageous industries such as cultural tourism, agriculture and animal husbandry, digital technology and Tibetan medicine, and accelerated the cultivation of emerging industries such as plateau light industry.

    Green development is also a benefit to people’s livelihood. The region has always prioritized eco-environmental conservation and has become one of the world’s healthiest eco-environment regions.

    In Wednesday’s meeting, Xi called on the region to promote ecological conservation, and to make coordinated efforts to cut carbon emissions, reduce pollution, expand green development and pursue economic growth, so as to protect “the roof of the world” and “the water tower of Asia.”

    For more information, please click:

    https://news.cgtn.com/news/2025-08-21/How-China-s-Xizang-achieves-great-progress-in-development-prosperity-1G0MYtI6VSo/p.html

  • Best Synthetic Urine Brand for 2025: Upass Takes the Top Spot

    United States – [20-08-2025] – An independent review of the leading synthetic urine brands available in the United States has named Upass Synthetic Urine, manufactured by SafeguardLabs, as the Best Synthetic Urine Brand for 2025.

    The annual review, conducted by the Industrial Market Research Group, evaluated publicly available product specifications, official brand documentation, and third-party data to measure performance in four key categories: composition accuracyformat and usabilityshelf life, and brand reliability. The 2025 analysis revealed measurable differences between top products, with Upass emerging as the market leader.

    Unmatched Realism in Composition Upass earned the highest marks for chemical accuracy and overall realism. According to the research, the formulation comes remarkably close to the composition of natural human urine, with precise balances of pHspecific gravitycreatinineureauric acid, and additional trace elements. These parameters are critical to authenticity, and in Upass, they are matched to a degree that meets or exceeds calibration standards used in some professional testing laboratories.

    Laboratory-Grade Calibration Quality In addition to its accurate chemical profile, Upass reproduces the visual and physical characteristics of fresh human urine, including realistic foam formation, clarity, and natural coloration. Its subtle scent and foam behavior further reinforce its authenticity. The review noted that certain laboratories employ Upass for equipment calibration purposes—an endorsement that underscores its scientific precision.

    Shelf Life and Packaging Innovation Upass also scored strongly for packaging and shelf stability. The product is shipped in a sealed, contamination-resistant container that protects it from environmental changes, extending its shelf life compared to competing brands. Its ready-to-use format, combined with clear storage guidelines, contributes to consistent quality over time.

    Brand Reliability and History SafeguardLabs, the manufacturer of Upass, has maintained a steady presence in the synthetic urine market for over a decade. Known for consistent quality control and adherence to published specifications, the company’s reliability was a key factor in securing the top ranking. The review found no significant discrepancies between Upass’s claimed specifications and independent measurements.

    A Clear Market Leader for 2025 “With measurable performance advantages in composition accuracy, realism, and packaging, Upass sets the current standard for synthetic urine products,” said Mark Wiseberg, lead analyst at Industrial Market Research Group. “Its chemical fidelity to natural human urine and proven shelf stability make it the clear choice for both consumers and industry professionals.”

    The full review includes comparative analysis of other leading brands in the market, detailing how they ranked in each test category. These findings are available upon request for industry stakeholders, laboratories, and regulatory bodies seeking further technical detail.

     

    Media Contact
    Company Name: Industrial Market Research Group
    Contact Person: Mark Wiseberg
    Email: Media@marketresearchgroup.com
    Country: United States
    Website: https://safeguardlabs.com/

  • CMS (867.HK, 8A8.SG) Reports Growth in Revenue and Profit for H1 2025, Strategic Transformation Unlocks New Drivers

    SHENZHEN, CHINAOn 18 August, China Medical System Holdings Limited (“CMS” or the “Company”) announced its interim results for the six months ended 30 June 2025 (the “Reporting Period”), with both revenue and profit recording year-on-year growth, demonstrating the initial results of its strategic transformation. During the Reporting Period, the Company recorded revenue of approximately RMB4.00 billion, representing a year-on-year increase of 10.8%. In the case that all medicines were directly sold by the Company, revenue would be approximately RMB4.67 billion, up 8.9% year-on-year. Net profit was approximately RMB0.93 billion, representing an increase of 3.1% year-on-year.

    The results reflect that CMS has emerged from the shadow of National Volume-based Procurement (“National VBP”), and its performance is expected to return to a sustainable growth trajectory. Revenue from the Company’s key non-National VBP exclusive/branded products and innovative products (in the case that all medicines were directly sold by the Company) reached approximately RMB2.90 billion, up 20.6% year-on-year, accounting for 62.1% of total revenue. The company’s exclusive/branded products and innovative products have a favorable competitive landscape and high visibility of future growth, and have now become the main drivers of performance growth.

    According to the interim results announcement, the company has been planning its “New CMS” blueprint since 2018, anchored on the three strategic pillars of “product innovation, commercial model reform, and international expansion” to build a sustainable second growth curve. By the first half of 2025, solid operating results and the steady delivery of innovation outcomes have confirmed that the Company’s strategic upgrade has been gradually translated into tangible achievements.

    “New Products” Strategy Drives Innovation Value Realization and Solidifies Growth Momentum

    At the forefront of the Company’s three strategic pillars, the “product innovation” strategy leverages a three-dimensional innovation mechanism of “overseas licensing, domestic collaboration, and in-house R&D” to continuously inject high-value short-, medium- and long-term pipelines, serving as a key growth engine. Currently, the innovation strategy has entered a period of continuous harvest, with new products continuously releasing commercial and clinical value.

    To date, the Company has successfully commercialized five innovative drugs in China; By 2025, two innovative products — ruxolitinib cream and Desidustat Tablets—are also expected to receive marketing approvals. Ruxolitinib cream is the first and only topical JAK inhibitor approved by the U.S. FDA and the European Medicines Agency for repigmentation in non-segmental vitiligo, and is expected to become the first approved treatment for vitiligo in China, filling a market gap and bringing new hope to Chinese vitiligo patients. Additionally, the New Drug Application (NDA) for the Alzheimer’s disease drug ZUNVEYL in China was accepted in July this year; the consumer healthcare product Poly-L-lactic Acid Microparticle Filler Injection has been approved for marketing, further enriching the Company’s diversified product portfolio.

    Among the innovative pipeline under R&D, several blockbuster candidates have entered the late-stage clinical development in China and are expected to be commercialized within the next one to three years, forming a new driving force for sustained growth.

    Among these, the collaborative product Y-3 for Injection has completed Phase III clinical trials in China. This product is an original unimolecular Class 1 innovative drug and the only non-peptide PSD95/nNOS uncoupler that has entered clinical development, with potential to become the first dual-function brain cytoprotectant for treating ischemic stroke while preventing post-stroke depression and anxiety. Another oral small molecule Class 1 innovative drug, ABP-671 (a URAT1 inhibitor) for the treatment of gout and hyperuricemia, is progressing through Phase IIb/III clinical trials in China. Compared with existing mainstream drugs, ABP-671 has the potential to reduce uric acid to lower levels at lower doses and possesses gout-tophus dissolution capability, thereby offering patients a more effective and safer treatment option.

    CMS continues to expand its innovative pipeline and enhance its end-to-end innovation capabilities to ensure the steady, phased marketing approval of innovative products. In H1 2025, two new collaborative R&D innovative products — ZUNVEYL and MG-K10 (a long-acting anti-IL-4Rα humanized monoclonal antibody injection) — were added to the portfolio. To date, the Company has deployed about 40 differentiated innovative pipeline products, including approximately 20 in-house R&D projects.

     

    Advancing “New Models” and “New Markets” Strategies to Unlock Multi-dimensional Growth

    According to the interim results announcement, CMS continues to advance its “New Models — Commercial Model Reform” strategy, forging anti-cyclical resilience through a diversified ecosystem. It also firmly implements its “New Markets – International Expansion” strategy, building a multi-dimensional growth framework via an industrial internationalization model.

    Under the commercial model reform strategy, the Company continues to focus on specialty therapeutic fields while expanding into new retail and new media channels, building a comprehensive marketing and promotion system that covers both “in-hospital + out-of-hospital” and “online + offline” channels, and reinforcing its diversified product portfolio with consumer attributes. Its skin health business, Dermavon, has demonstrated strong potential in this particular segment with consumer attributes. Since its independent operation in 2021, Dermavon has achieved dual leadership in both the “coverage of dermatology indications” and the “revenue scale of dermatological prescription drugs”, and is proposed to be spun off and separately listed on the Main Board of the Hong Kong Stock Exchange by way of introduction and distribution in specie, to further unlock its standalone value and high-growth potential.

    In terms of internationalization, CMS successfully completed its secondary listing on the Main Board of the Singapore Exchange by way of introduction on 15 July 2025, marking a new milestone in its “industrial internationalization” strategy. With Singapore as a hub, the Company has established a comprehensive business system covering the entire value chain of “R&D–Manufacturing–Commercialization” for emerging markets. To date, its commercial platform company, Rxilient, has cumulatively submitted nearly 20 registration applications for pharmaceutical products and medical devices across Southeast Asia, the Middle East, Hong Kong, Macau, and Taiwan Region, covering therapeutic fields such as dermatology, ophthalmology, oncology, autoimmune, and central nervous system. Ruxolitinib cream (vitiligo indication) has been approved for marketing in Macau and Hong Kong, and its registration applications have been submitted in Singapore and Taiwan Region. Intravenous Toripalimab (the first China-originated anti-PD-1 monoclonal antibody drug that has been approved by the China NMPA and the U.S. FDA) has been submitted for registration in five countries, including Malaysia. Tildrakizumab Injection and Sucroferric Oxyhydroxide Chewable Tablets have also been approved for marketing in Hong Kong. Meanwhile, PharmaGend, an associate CDMO manufacturing facility in which CMS holds a 45.0% equity interest, now has an annual production capacity of 1 billion units of oral solid dosage forms (tablets and capsules), and has obtained a drug manufacturing license from Singapore’s HSA, U.S. FDA cGMP certification, and passed Swiss QP audits. The construction of new production lines for nasal sprays, creams, and injectables is progressing steadily, providing high-standard production and delivery capabilities for the international market.

    Looking ahead, the growth logic of “New CMS” is expected to accelerate its realization, with profitability and performance resilience improving simultaneously. The Company is building a growth framework centered on differentiated innovation, driven by a synergistic and diversified ecosystem, and underpinned by an international footprint. This will open up long-term opportunities for high-quality development, deliver quality pharmaceutical products and services to patients worldwide, and generate sustainable returns for shareholders.

     

    About CMS

    CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.

     

    CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.

     

    CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries, strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology/ophthalmology/ skin health businesses. Among them, the skin health business has become a leading enterprise in its field, bringing economies of scale in specialty therapeutic fields. Meanwhile, CMS continuously deepens its business development in the Southeast Asia and Middle East regions, further escorting the sustainable and healthy development.

     

    CMS Disclaimer and Forward-Looking Statements

    This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.

     

    This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

     

    Media Contact

    Brand: China Medical System Holdings Ltd.

    Contact: CMS Investor Relations

    Email: ir@cms.net.cn

    Website: https://web.cms.net.cn/en/home/

    Source: China Medical System Holdings Ltd.

  • CMS (867.HK, 8A8.SG) Reports Growth in Revenue and Profit for H1 2025, Strategic Transformation Unlocks New Drivers

    SHENZHEN, CHINAOn 18 August, China Medical System Holdings Limited (“CMS” or the “Company”) announced its interim results for the six months ended 30 June 2025 (the “Reporting Period”), with both revenue and profit recording year-on-year growth, demonstrating the initial results of its strategic transformation. During the Reporting Period, the Company recorded revenue of approximately RMB4.00 billion, representing a year-on-year increase of 10.8%. In the case that all medicines were directly sold by the Company, revenue would be approximately RMB4.67 billion, up 8.9% year-on-year. Net profit was approximately RMB0.93 billion, representing an increase of 3.1% year-on-year.

    The results reflect that CMS has emerged from the shadow of National Volume-based Procurement (“National VBP”), and its performance is expected to return to a sustainable growth trajectory. Revenue from the Company’s key non-National VBP exclusive/branded products and innovative products (in the case that all medicines were directly sold by the Company) reached approximately RMB2.90 billion, up 20.6% year-on-year, accounting for 62.1% of total revenue. The company’s exclusive/branded products and innovative products have a favorable competitive landscape and high visibility of future growth, and have now become the main drivers of performance growth.

    According to the interim results announcement, the company has been planning its “New CMS” blueprint since 2018, anchored on the three strategic pillars of “product innovation, commercial model reform, and international expansion” to build a sustainable second growth curve. By the first half of 2025, solid operating results and the steady delivery of innovation outcomes have confirmed that the Company’s strategic upgrade has been gradually translated into tangible achievements.

    “New Products” Strategy Drives Innovation Value Realization and Solidifies Growth Momentum

    At the forefront of the Company’s three strategic pillars, the “product innovation” strategy leverages a three-dimensional innovation mechanism of “overseas licensing, domestic collaboration, and in-house R&D” to continuously inject high-value short-, medium- and long-term pipelines, serving as a key growth engine. Currently, the innovation strategy has entered a period of continuous harvest, with new products continuously releasing commercial and clinical value.

    To date, the Company has successfully commercialized five innovative drugs in China; By 2025, two innovative products — ruxolitinib cream and Desidustat Tablets—are also expected to receive marketing approvals. Ruxolitinib cream is the first and only topical JAK inhibitor approved by the U.S. FDA and the European Medicines Agency for repigmentation in non-segmental vitiligo, and is expected to become the first approved treatment for vitiligo in China, filling a market gap and bringing new hope to Chinese vitiligo patients. Additionally, the New Drug Application (NDA) for the Alzheimer’s disease drug ZUNVEYL in China was accepted in July this year; the consumer healthcare product Poly-L-lactic Acid Microparticle Filler Injection has been approved for marketing, further enriching the Company’s diversified product portfolio.

    Among the innovative pipeline under R&D, several blockbuster candidates have entered the late-stage clinical development in China and are expected to be commercialized within the next one to three years, forming a new driving force for sustained growth.

    Among these, the collaborative product Y-3 for Injection has completed Phase III clinical trials in China. This product is an original unimolecular Class 1 innovative drug and the only non-peptide PSD95/nNOS uncoupler that has entered clinical development, with potential to become the first dual-function brain cytoprotectant for treating ischemic stroke while preventing post-stroke depression and anxiety. Another oral small molecule Class 1 innovative drug, ABP-671 (a URAT1 inhibitor) for the treatment of gout and hyperuricemia, is progressing through Phase IIb/III clinical trials in China. Compared with existing mainstream drugs, ABP-671 has the potential to reduce uric acid to lower levels at lower doses and possesses gout-tophus dissolution capability, thereby offering patients a more effective and safer treatment option.

    CMS continues to expand its innovative pipeline and enhance its end-to-end innovation capabilities to ensure the steady, phased marketing approval of innovative products. In H1 2025, two new collaborative R&D innovative products — ZUNVEYL and MG-K10 (a long-acting anti-IL-4Rα humanized monoclonal antibody injection) — were added to the portfolio. To date, the Company has deployed about 40 differentiated innovative pipeline products, including approximately 20 in-house R&D projects.

     

    Advancing “New Models” and “New Markets” Strategies to Unlock Multi-dimensional Growth

    According to the interim results announcement, CMS continues to advance its “New Models — Commercial Model Reform” strategy, forging anti-cyclical resilience through a diversified ecosystem. It also firmly implements its “New Markets – International Expansion” strategy, building a multi-dimensional growth framework via an industrial internationalization model.

    Under the commercial model reform strategy, the Company continues to focus on specialty therapeutic fields while expanding into new retail and new media channels, building a comprehensive marketing and promotion system that covers both “in-hospital + out-of-hospital” and “online + offline” channels, and reinforcing its diversified product portfolio with consumer attributes. Its skin health business, Dermavon, has demonstrated strong potential in this particular segment with consumer attributes. Since its independent operation in 2021, Dermavon has achieved dual leadership in both the “coverage of dermatology indications” and the “revenue scale of dermatological prescription drugs”, and is proposed to be spun off and separately listed on the Main Board of the Hong Kong Stock Exchange by way of introduction and distribution in specie, to further unlock its standalone value and high-growth potential.

    In terms of internationalization, CMS successfully completed its secondary listing on the Main Board of the Singapore Exchange by way of introduction on 15 July 2025, marking a new milestone in its “industrial internationalization” strategy. With Singapore as a hub, the Company has established a comprehensive business system covering the entire value chain of “R&D–Manufacturing–Commercialization” for emerging markets. To date, its commercial platform company, Rxilient, has cumulatively submitted nearly 20 registration applications for pharmaceutical products and medical devices across Southeast Asia, the Middle East, Hong Kong, Macau, and Taiwan Region, covering therapeutic fields such as dermatology, ophthalmology, oncology, autoimmune, and central nervous system. Ruxolitinib cream (vitiligo indication) has been approved for marketing in Macau and Hong Kong, and its registration applications have been submitted in Singapore and Taiwan Region. Intravenous Toripalimab (the first China-originated anti-PD-1 monoclonal antibody drug that has been approved by the China NMPA and the U.S. FDA) has been submitted for registration in five countries, including Malaysia. Tildrakizumab Injection and Sucroferric Oxyhydroxide Chewable Tablets have also been approved for marketing in Hong Kong. Meanwhile, PharmaGend, an associate CDMO manufacturing facility in which CMS holds a 45.0% equity interest, now has an annual production capacity of 1 billion units of oral solid dosage forms (tablets and capsules), and has obtained a drug manufacturing license from Singapore’s HSA, U.S. FDA cGMP certification, and passed Swiss QP audits. The construction of new production lines for nasal sprays, creams, and injectables is progressing steadily, providing high-standard production and delivery capabilities for the international market.

    Looking ahead, the growth logic of “New CMS” is expected to accelerate its realization, with profitability and performance resilience improving simultaneously. The Company is building a growth framework centered on differentiated innovation, driven by a synergistic and diversified ecosystem, and underpinned by an international footprint. This will open up long-term opportunities for high-quality development, deliver quality pharmaceutical products and services to patients worldwide, and generate sustainable returns for shareholders.

     

    About CMS

    CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.

     

    CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.

     

    CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries, strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology/ophthalmology/ skin health businesses. Among them, the skin health business has become a leading enterprise in its field, bringing economies of scale in specialty therapeutic fields. Meanwhile, CMS continuously deepens its business development in the Southeast Asia and Middle East regions, further escorting the sustainable and healthy development.

     

    CMS Disclaimer and Forward-Looking Statements

    This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.

     

    This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

     

    Media Contact

    Brand: China Medical System Holdings Ltd.

    Contact: CMS Investor Relations

    Email: ir@cms.net.cn

    Website: https://web.cms.net.cn/en/home/

    Source: China Medical System Holdings Ltd.

  • CGTN: How China’s ‘two mountains’ concept is shaping global green development

    CGTN published an article exploring the significance of China’s “two mountains” concept, a green growth philosophy that is central to the country’s ecological efforts and serves as an inspiration for global sustainable development.

    Erik Solheim recalled that over a decade ago, he was too worried about smog in Beijing to even run outdoors. Today, the former executive director of the United Nations Environment Programme makes time for morning runs whenever he returns to the city.

    During a jog this year, Solheim noted that most vehicles on the road were “quiet, pollution-free, cost-effective” new energy vehicles, a visible transformation that reflects a deep shift in China’s green growth philosophy – one rooted in a concept articulated by President Xi Jinping: “Lucid waters and lush mountains are invaluable assets.”

    The “two mountains” concept, which literally means green mountains and clear waters are as valuable as mountains of gold and silver, has become a guiding principle for China’s ecological efforts and a source of inspiration for sustainable development worldwide.

    As President Xi has said, “Harmony between man and nature is a defining feature of Chinese modernization. China is a steadfast actor and major contributor in promoting global green development.”

    A philosophy that guides real change

    First put forward in 2005 during Xi’s visit to Yucun Village in east China’s Zhejiang Province, the “two mountains” concept has transformed from a local slogan into a cornerstone of China’s national strategy.

    Today, China leads the world in renewable energy deployment. It had installed nearly 1.889 billion kilowatts of total renewable capacity by the end of 2024, including approximately 887 million kilowatts of solar, 521 million kilowatts of wind and 436 million kilowatts of hydropower, which accounted for 56 percent of the nation’s total power capacity and supplied about 35 percent of its electricity generation.

    The “two mountains” concept has sparked interest well beyond China. A global opinion poll released by CGTN, covering 24,515 respondents from 48 countries, showed that 81.6 percent of global respondents believe the concept has broken the traditional “polluting first and cleaning up later” model of growth.

    Clifford Cobb, a leading ecological economist in the United States, has closely followed China’s environmental path. He believes the idea presents a new model of development.

    “Over the past 20 years, China has proven that it’s possible to protect nature while generating economic value,” Cobb said. “It’s a win-win vision the world can learn from.”

    Promoting international cooperation for a greener future

    China’s green development vision is helping power global cooperation. A vivid example can be found on the vast steppes of northern Kazakhstan’s Akmola Region, where renewable energy is transforming the local economy.

    Engineer Khasabay Kinlosan is part of that change. Every day, he maintains more than 40 wind turbines that are part of a major Belt and Road cooperation project between China and Kazakhstan. These turbines produce over 800 million kilowatt-hours of clean electricity annually, cutting carbon emissions by 650,000 tonnes.

    As the Belt and Road Initiative moves into a new stage of high-quality development, the “two mountains” philosophy is finding growing resonance abroad.

    Almas Chukin, a prominent Kazakh economist, says the concept struck a chord with him. “China has become a leader in solar and wind power, and it is addressing global challenges such as climate change through action, not just words,” he said.

    China’s commitment to a shared green future goes far beyond Central Asia. It has supported low-carbon development and ecological capacity building in more than 100 developing countries, particularly small island nations and African states.

    Through multilateral platforms like the South-South Climate Cooperation Initiative and the Belt and Road’s Green Development Partnership, China is exporting not only technologies but also growth models and sustainability know-how.

    Its contributions to global biodiversity are equally notable. In 2022, China hosted COP15 of the Convention on Biological Diversity, helping broker the landmark Kunming-Montreal Global Biodiversity Framework. UN officials noted that the agreement’s success owes much to China’s long-standing emphasis on a “whole-of-society” approach to environmental governance.

    “President Xi’s ecological civilization thought holds great theoretical value and has also proven highly effective in practice,” said Eliason Kaganga, a Tanzanian scholar focused on protecting Lake Victoria. “China’s solutions – especially those that empower local people – are bringing lasting benefits to African countries and communities.”

    https://news.cgtn.com/news/2025-08-16/How-China-s-two-mountains-concept-shapes-global-green-development-1FSGt4l2H9C/p.html

  • Back-to-School Meets Tennis Grand Slam: PINSPARK’s Stylish Activewear Kicks Off the New Semester with Limited-Time Offers

    As the fall semester approaches and the US Open draws near, students and families are entering the prime season for refreshing their sportswear. Aligning with the dual themes of “Back to School in Style” and “Spark the Semester,” PINSPARK launches a special back-to-school promotion. Offering tennis apparel that blends professional functionality with fashionable design, PINSPARK empowers students to embrace the new term in comfort while experiencing the vibrant energy of tennis.

    Limited-Time Back-to-School Offers: Unlock a Stylish Activewear Experience

    To help customers refresh their back-to-school wardrobes, PINSPARK introduces multiple exclusive back-to-school promotions:

    Direct Item Discounts: During the promotional period, selected PINSPARK activewear items enjoy 10%-18% off.

    Bundle Special Offers: Purchase the two recommended designated sets (sports bra + tennis skirt) to be eligible for an exclusive 10% discount on the bundle. This one-stop purchase enables you to complete your professional tennis gear configuration in full, delivering enhanced cost-effectiveness.

    This limited-time offer is now live. Students and parents are encouraged to check PINSPARK’s official channels early, secure their favorite items, and start the new semester with stylish, affordable activewear.

    Award-Winning Star Product: 2025 New York Product Design Award Silver Winner Tennis Skirt

    The featured PINSPARK women’s tennis skirt for this back-to-school season has earned the Silver Award at the 2025 New York Product Design Awards, standing out as a core piece that balances function and aesthetics. Key design and material highlights include:

    • Performance-Oriented Design: Engineered for tennis-specific movements, the skirt features a wide waistband and a deep V-back cut, accentuating body lines without constricting the abdomen. The elongated hemline adds dynamic elegance, achieving a unique look through minimalist design.
    • Practical Details: The built-in shorts include two side pockets—one on the left with an ergonomically inverted design for easy tennis ball access, and another on the right to securely hold small items like phones, making it ideal for both sports and daily wear.
    • Comfortable Materials & Craftsmanship: Crafted from high-stretch cotton-nylon blend fabric with 4-needle, 6-thread flatlock stitching to minimize chafing and maximize flexibility. A mesh inner lining ensures rapid moisture-wicking, keeping you dry even during intense matches.

    Back-to-School Styling Guide: One Outfit for Sports and Everyday Life

    PINSPARK offers two highly versatile outfit combinations tailored for students, seamlessly transitioning between tennis, campus life, and casual outings:

    Outfit 1: Professional Tennis Set

    • Top: PINSPARK Women’s Sports Brawith Built-in Padded Bra (V-neck long style, removable pads for enhanced support and fit)
    • Bottom: 2025 New York Product Design Award Silver Winner Tennis Skirt (pleated design with pocketed shorts, suitable for both performance and casual wear)

    Outfit 2: Multi-Scenario Activewear Set

    PINSPARK: Igniting the Spark Between Sport and Style

    Focused on the needs of young consumers and families, PINSPARK specializes in stylish activewear, seamlessly blending professional performance with everyday fashion. Guided by the philosophy of “Making sport stylish and daily life more dynamic,” the brand optimizes its products for diverse activities such as tennis, yoga, and pickleball. Designed to meet the demands of high-intensity workouts while effortlessly transitioning into campus commutes and post-class relaxation, PINSPARK stands as a top choice for quality and style.

    This back-to-school season, join PINSPARK in welcoming the new semester with style and comfort, while embracing the excitement of tennis. For more details on promotions and products, visit the PINSPARK official website, Amazon flagship store, or follow our social media channels for real-time updates—secure your limited-time offers and ignite a vibrant, stylish new semester!

    PINSPARK

    Charlotte Liu

    pr@pinspark.com

    New York, US

    https://pinspark.com

  • COOFANDY Teams Up with New York Celebrity Stylist Britt Theodora to Launch a Joint Collection, Unlocking Diverse Fashion Codes for Men

    What kind of sparks will fly when a classic men’s wear brand meets a New York fashion maverick?

    Recently, the men’s apparel brand COOFANDY officially announced its collaboration with Britt Theodora, a renowned New York stylist, to create a joint collection— “COOFANDY’s Signature Looks Curated By Britt Theodora”. This collection brings together eight complete men’s outfits personally selected and paired by Britt Theodora. It aims to meet the diverse dressing needs of modern men in various life scenarios, representing another fashionable practice of the brand’s “Dress the Journey” philosophy.

    Powerhouse Collaboration: Classic Men’s Wear Brand Meets Fashion Pioneer

    As a highly regarded stylist in New York’s fashion scene, Britt Theodora is well-known for her unique insights into modern and stylish men’s wear, with her work consistently catching the attention of top celebrities and fashion critics. She is not only the long-term styling partner of the famous comedian Pete Davidson, particularly renowned for crafting his stunning Met Gala red-carpet looks, but has also played a significant role in shaping the public images of numerous well-known men in the entertainment industry, such as Hart Denton. Britt Theodora’s successful collaborations with international brands like Google Pixel and David Webb have further solidified her authority in the field of fashion styling. Her signature “Energy Styling” philosophy seamlessly blends effortless coolness with meticulous attention to detail, continuously infusing styles with confidence, a sense of purpose, and a forward-thinking perspective.

    This joint collaboration marks an exciting collision of sparks between Britt Theodora and COOFANDY. COOFANDY is committed to accompanying men on their growth journey, providing dressing solutions for different stages of life. On the other hand, Britt Theodora, as a wizard in the fashion world, excels at skillfully combining diverse elements to carve out unique style imprints for individuals. This joint collection is the crystallization of both parties’ philosophies: Britt Theodora utilized her exceptional styling skills to handpick items from COOFANDY’s extensive product range, from the men’s shirt series to the men’s T-shirt series, and carefully assembled eight complete looks that cover a wide range of styles and occasions, offering fans an excellent opportunity to purchase their ideal outfits in one go.

    OOTD Inspiration: Britt Theodora’s Curated Collection Looks Unlock All-Scenario Style

    The core highlight of this collection lies in its strong style inclusivity and scenario adaptability:

    Diverse Styles, All Covered

    The collection includes classic yet reimagined, personality-showcasing suit sets; casual shirts that balance comfort and fashion; versatile and practical casual trousers that effortlessly display taste; as well as sportswear that combines functionality with trendiness.

    Full Scenario Coverage, Unlocking Versatile Style

    Through eight outfits, Britt Theodora clearly demonstrates dressing templates for five classic men’s life scenarios:

    • Business Commute Style: Neat and efficient, exuding professional confidence.
    • Relaxed Vacation Style: Light and comfortable, allowing one to fully enjoy leisure time.
    • Casual Weekend Style: Easygoing and spontaneous, revealing an effortless sense of chic.
    • Romantic Date Style: Exquisite and well-considered, radiating irresistible charm.
    • Comfortable Sports Style: Energetic and dynamic, combining style with functionality.

    Britt Theodora‘s profound styling expertise is evident in every outfit. For instance, one outfit might focus on a business commute solution, featuring COOFANDY’s crisp casual blazer, paired with a high-quality, solid-colored shirt and well-tailored elastic formal trousers. Through material contrasts and clean lines, it creates a professional yet modern commuting image.

    Another relaxed vacation-style outfit might center around a breathable and comfortable Hawaiian short-sleeved shirt, matched with casual-fit long trousers and lightweight casual shoes. By cleverly using earth tones and pure cotton materials, it creates a relaxed and pleasant holiday atmosphere. Each outfit is a vivid manifestation of Britt Theodora’s “Energy Styling” philosophy, helping the wearer boost confidence and precisely express themselves.

    Continuing Collaboration: From Live Stream Interaction to Joint Creation

    The launch of this co-branded collection marks a further deepening of the collaboration between Britt Theodora and COOFANDY. As early as July 10th last month, Britt Theodora made a surprise appearance as a special guest at COOFANDY’s brand live stream event. During that live stream, she not only shared cutting-edge men’s fashion matching trends but also delivered vivid styling demonstrations for the audience on the spot. Her professional vision and unique insights garnered enthusiastic responses from the online viewers, becoming one of the highlights of the evening. This in-depth co-branded endeavor undoubtedly propels their partnership from online interaction to a new pinnacle of jointly creating physical products, making it more tangible and accessible.

    Currently, the entire “COOFANDY’s Signature Looks Curated By Britt Theodora” collection is available on COOFANDY’s official Amazon store. Whether you need to enhance your workplace image, plan your vacation wardrobe, create the perfect date look, or find comfortable everyday outfits, the eight distinctively styled outfits carefully planned by Britt Theodora will serve as an inspiring wardrobe for you to explore your personal style and confidently navigate different life scenarios.

    About COOFANDY

    COOFANDY is an international brand dedicated to meeting the dressing needs of modern men. Adhering to the “Dress the Journey” philosophy, it is committed to providing men with high-quality, stylish, and cost-effective clothing options at every stage of life, accompanying them on their growth journey and exploring diverse styles.

    About Britt Theodora

    Britt Theodora is a well-known New York-based stylist highly regarded in the industry for her modern and stylish men’s wear styling. She has collaborated with numerous top celebrities and international brands, and her unique “Energy Styling” philosophy focuses on infusing styles with confidence and a sense of purpose. Her clients include Pete Davidson, Hart Denton, etc., and her collaborative brands cover Google Pixel, David Webb, etc.

    For more information, please visit the COOFANDY website and Amazon storefront, or connect with COOFANDY on Facebook and Instagram.

    COOFANDY

    Charlotte Liu

    pr@coofandy.com

    New York, US

    https://coofandy.com

  • Hefei Grand Nets (SUGRAND) Gains Global Market Share with Sustainable Plastic Netting Solutions

    Hefei Grand Nets Co., Ltd., better known as SUGRAND, has earned a global reputation as a leading manufacturer of HDPE plastic netting and shade fabric. Established in 2008, The company’s one-stop service model ensures that customers receive clear communication and transparency throughout the entire order process, from sample approval to final delivery.the company now exports to over 50 countries, serving agriculture, construction, and outdoor living sectors with durable, UV-stabilized netting solutions.

    What sets SUGRAND apart is its broad product line, which includes shade nets, insect nets, bird nets, olive net, ground cover fabrics, scaffold nets, mulch film, and more. These products are widely used to protect crops, enhance outdoor comfort, and ensure construction site safety. With up to 5–10 years of service life for many nets, SUGRAND’s products are especially popular among farmers, contractors, and homeowners seeking long-lasting value.

    Compared to smaller competitors, SUGRAND stands out for its vertical integration. The company owns a modern factory ,factory area over 66600and its operations are ISO- and CE-certified. This allows the brand to offer strict quality control, fast delivery, and custom solutions at competitive prices.

    Sustainability is also core to SUGRAND’s identity. Its netting is made from non-toxic, recyclable HDPE materials that meet international environmental standards. By reducing the need for pesticides and extending product lifespan, SUGRAND’s agricultural and shade solutions help customers protect the planet as well as their investments.

    Over 17 years, SUGRAND has become more than a manufacturer — it’s a trusted global supplier known for its product innovation, customer support, and reliability. Whether it’s protecting a vineyard, securing a job site, or shading a backyard, SUGRAND offers the right solution backed by industry experience and international quality.

    Media Contact: 
    Company Name:Hefei Grand Nets Co., Ltd. (SUGRAND) |
    Address:15 Floor, B Tower, Jin Zhong Huan Mansion, Hefei, China
    Tel: +86-551-62531962
    +86-156-0560-7108
    Email: 
    sugrand@grandnets.com 
    Website: 
    www.grandnets.com